



(51) International Patent Classification:

A61K 39/395 (2006.01) G01N 33/567 (2006.01)
G01N 33/53 (2006.01)

(21) International Application Number:

PCT/US2008/083659

(22) International Filing Date:

14 November 2008 (14.11.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/988,481 16 November 2007 (16.11.2007) US
61/019,747 8 January 2008 (08.01.2008) US

(71) Applicant (for all designated States except US): **THE ROCKEFELLER UNIVERSITY** [US/US]; 1230 York Avenue, New York, NY 10021-6399 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RAVETCH, Jeffrey** [US/US]; 500 Park Avenue, New York, NY 10022 (US). **FUKUYAMA, Hidehiro** [JP/FR]; Strasbourg (FR).

(74) Agents: **NORTON, Gerard, P.** et al.; Fox Rothschild LLP, 997 Lenox Drive, Bldg. #3, Lawrenceville, NJ 08648 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

30 December 2009

(54) Title: ANTIBODIES SPECIFIC FOR THE PROTOFIBRIL FORM OF BETA-AMYLOID PROTEIN


A β fibrillogenesis

FIG. 1

(57) Abstract: Isolated antibodies have been characterized which show specific affinity to a repeating conformational epitope of a protofibril form of the human β -amyloid peptide as compare to low molecular weight forms of β -amyloid peptide. These isolated antibodies and related pharmaceutically effective compositions may be useful in the therapeutic and/or prophylactic treatment of Alzheimer's disease by effectively blocking the ability of the protofibril form of β -amyloid peptide to form fibril forms linked with complications associated with Alzheimer's disease. The isolated antibodies of the present invention are also useful in various diagnostic assays and associated kits.